Cargando…

Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR(+), HER2(−) advanced breast cancer: results from BOLERO-2

BACKGROUND: The current analysis was performed to evaluate the impact of PIK3CA hotspot mutations on everolimus efficacy in BOLERO-2 participants, using cell-free DNA (cfDNA) from plasma samples collected at the time of patient randomisation. METHODS: PIK3CA H1047R, E545K, and E542K mutations in pla...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moynahan, Mary Ellen, Chen, David, He, Wei, Sung, Patricia, Samoila, Aliaksandra, You, Daoqi, Bhatt, Trusha, Patel, Parul, Ringeisen, Francois, Hortobagyi, Gabriel N, Baselga, Jose, Chandarlapaty, Sarat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355930/ https://www.ncbi.nlm.nih.gov/pubmed/28183140 http://dx.doi.org/10.1038/bjc.2017.25

Ejemplares similares

Everolimus plus exemestane as first-line therapy in HR(+), HER2(−) advanced breast cancer in BOLERO-2
por: Beck, J. Thaddeus, et al.
Publicado: (2013)

Everolimus Plus Exemestane in Postmenopausal Patients with HR(+) Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
por: Yardley, Denise A., et al.
Publicado: (2013)

Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR(+) Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
por: Yardley, Denise A., et al.
Publicado: (2014)

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas
por: Black, Jonathan D, et al.
Publicado: (2015)

Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1
por: Toi, Masakazu, et al.
Publicado: (2017)

Everolimus Plus Exemestane for the Treatment of Advanced Breast Cancer: A Review of Subanalyses from BOLERO-2()
por: Hortobagyi, Gabriel N.
Publicado: (2015)

Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo
por: Cocco, Emiliano, et al.
Publicado: (2016)

Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours
por: Campone, M, et al.
Publicado: (2009)

Aberrant activation of the mTOR pathway and anti-tumour effect of everolimus on oesophageal squamous cell carcinoma
por: Hirashima, K, et al.
Publicado: (2012)

Effects of preset sequential administrations of sunitinib and everolimus on tumour differentiation in Caki-1 renal cell carcinoma
por: Santos, C D, et al.
Publicado: (2015)

Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapy
por: Sathe, A, et al.
Publicado: (2014)

FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo
por: Cejka, D, et al.
Publicado: (2009)

Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers
por: Khelwatty, Said A, et al.
Publicado: (2015)

Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs
por: Bianco, R, et al.
Publicado: (2008)

Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis
por: Damiano, V, et al.
Publicado: (2013)

EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy
por: Evans, A H, et al.
Publicado: (2010)

Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma
por: Voss, Martin H, et al.
Publicado: (2016)

HER2 expression as a potential marker for response to therapy targeted to the EGFR
por: Emlet, D R, et al.
Publicado: (2006)

Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma
por: De Silva, Nadeera, et al.
Publicado: (2015)

HER2 expression patterns in paired primary and metastatic endometrial cancer lesions
por: Halle, Mari Kyllesø, et al.
Publicado: (2018)

Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors
por: Vandamme, Timon, et al.
Publicado: (2016)

Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies
por: Tural, D, et al.
Publicado: (2014)

Anti-HER-2 DNA vaccine protects Syrian hamsters against squamous cell carcinomas
por: Berta, G N, et al.
Publicado: (2005)

Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma
por: Kawaguchi, Y, et al.
Publicado: (2007)

Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab
por: Todeschini, P, et al.
Publicado: (2011)

Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma
por: Peiró, G, et al.
Publicado: (2014)

Human responses against HER-2-positive cancer cells in human immune system-engrafted mice
por: De Giovanni, C, et al.
Publicado: (2012)

HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma
por: Liu, Y J, et al.
Publicado: (2014)

Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells
por: Konecny, G E, et al.
Publicado: (2008)

Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer
por: Lee, H J, et al.
Publicado: (2015)

Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo
por: Schwab, C L, et al.
Publicado: (2014)

Induction of effective and antigen-specific antitumour immunity by a liposomal ErbB2/HER2 peptide-based vaccination construct
por: Roth, A, et al.
Publicado: (2005)

Monitoring response to cytostatic cisplatin in a HER2(+) ovary cancer model by MRI and in vitro and in vivo MR spectroscopy
por: Pisanu, M E, et al.
Publicado: (2014)

Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancer
por: Seo, An Na, et al.
Publicado: (2016)

Caspase-dependent and -independent suppression of apoptosis by monoHER in Doxorubicin treated cells
por: Bruynzeel, A M E, et al.
Publicado: (2007)

Pooled peptides from HER-2/neu-overexpressing primary ovarian tumours induce CTL with potent antitumour responses in vitro and in vivo
por: Gritzapis, A D, et al.
Publicado: (2005)

HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer
por: Konecny, G E, et al.
Publicado: (2009)

EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy
por: Kumai, T, et al.
Publicado: (2013)

Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis
por: Yokoyama, H, et al.
Publicado: (2006)

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2
por: Rugo, H. S., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_os2n9livqtb0usajdn82aa53tq